Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 99-108

  Lathouwers, Erkki ^a   De Meyer, Sandra ^a   Dierynck, Inge ^a   Van De Casteele, Tom ^a   Lavreys, Ludo ^a   De Béthune, Marie Pierre ^a   Picchio, Gaston ^b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PLASMA; PRIORITY JOURNAL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENETIC ASSOCIATION STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PHOSPHONIC ACIDS; POLYMORPHISM, GENETIC; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 79951488200     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1719     Document Type: Article

References (33)

1. Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80:565-576. (Pubitemid 351358551)
2. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
3. US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-161. (Updated 1 December 2009. Accessed 09 February 2010.) Available from http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf
4. World Health Organization. Adherence to long-term therapies: evidence for action (2003). (Accessed 09 February 2010.) Available from http://apps.who.int/ medicinedocs/pdf/s4883e/s4883e.pdf
5. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321. (Pubitemid 40734460)
6. de Béthune MP, Hertogs K. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin 2006; 22:2603-2612. (Pubitemid 46048375)
7. Tibotec, Inc. PREZISTA™ (darunavir) prescribing information. (Updated January 2010. Accessed 09 February 2010.) Available from http://www.prezista.com
8. European Medicines Agency. PREZISTA™ (darunavir) summary of product characteristics (Updated October 2009. Accessed 09 February 2010.) Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/emea-combined- h707en.pdf
9. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
10. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
11. Cohen C. The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naive, HIV-infected patients. HIV Therapy 2009; 3:121-133.
12. Los Alamos National Laboratory. HIV-1 subtype and circulating recombinant form reference sequences (Accessed 09 February 2010.) Available from http://hiv.lanl.gov
13. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. 15th International HIV Drug Resistance Workshop. 13-17 June 2006, Sitges, Spain. Abstract 73.
14. Abbott Laboratories. KALETRA® (lopinavir/ritonavir) prescribing information. (Updated October 2009. Accessed 09 February 2010.) Available from http://www.kaletra.com
15. Boehringer Ingelheim. APTIVUS® (tipranavir) prescribing information. Boehringer Ingelheim (Updated June 2009. Accessed 09 February 2010.) Available from http://www.aptivus.com
16. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846. (Pubitemid 38328185)
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
18. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Atazanavir/ritonavir vs lopinavir/ritonavir in antiretroviral-naive HIV-1-infected patients: CASTLE 96 week efficacy and safety. 48th Annual ICAAC/IDSA. 25-28 October 2008, Washington, DC, USA. Abstract H-1250d.
19. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009 Top HIV Med 2009; 17:138-145.
20. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16:269-277. (Pubitemid 34118574)
21. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30. (Pubitemid 30432540)
22. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223. (Pubitemid 46036930)
23. Stanford University HIV Drug Resistance Database. Mutation prevalence according to subtype and treatment (Updated January 2010. Accessed 09 February 2010.) Available from http://hivdb.stanford.edu/cgi-bin/MutPrevBySubtypeRx.cgi
24. Nelson M, Girard PM, DeMasi R, et al. Adherence to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive, HIV-infected patients in ARTEMIS: 96-week data. 15th Annual Conference of the British HIV Association (BHIVA). 1-3 April 2009, Liverpool, UK. Abstract 0207.
25. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
26. De Wit M, Keuleers I, Gustin E, et al. Binding kinetics of protease inhibitors to wild-type and multi-drug resistant HIV-1 proteases: a mechanistic study of the genetic barrier to resistance of darunavir. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract M-166.
27. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
28. Pattery T, De Wolf H, Verlinden H, et al. Efficiency of HIV-1 PR-RT genotyping on clinical isolates with viral load less than 1000 copies/ml: a 12 year analysis. Reviews in Antiviral Therapy and Infectious Diseases. 2010; 1:3.
29. Zazzi M. Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based first-line antiretroviral treatment. Rev Antivir Ther 2007; 2:4-12.
30. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:261-268. (Pubitemid 38280651)
31. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40:288-293. (Pubitemid 41533068)
32. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50:367-374.
33. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476-482. (Pubitemid 44160731)